Africa's Billion Consumer Myth and What It Costs Women in Femtech and Healthcare

Investors and founders keep pitching Africa on population numbers. But a smaller, less glamorous truth sits underneath those slides, and it hits women in healthcare harder than anywhere else.

There is a pitch deck statistic that has become almost liturgical in African tech circles. "One billion consumers." It gets said with confidence, written in bold, and projected onto screens at conferences from Lagos to London. It is also, in most practical senses, a significant exaggeration.

The argument is not that Africa lacks people, or potential, or genuine commercial opportunity. It is that there is a meaningful gap between a continent of 1.4 billion people and a continent of 1.4 billion reliable paying consumers, and building businesses, especially in healthcare and femtech, without understanding that gap can be quietly devastating.

What Africa's Consumer Market Numbers Actually Show

In 2022, during a L'Oréal internship, a market researcher shared an insight that stuck: only around 2% of Nigerians, roughly 4 million people out of over 200 million, could consistently spend more than $10 a day on premium products. Africa's so-called "middle class" is typically defined as people spending between $2 and $20 daily, but much of that group sits closer to the $2 end, highly exposed to inflation, currency depreciation, and economic shocks.

Nigeria makes this concrete. The naira has lost significant purchasing power over the last several years. A consumer who looked like a "$10-a-day spender" on paper a few years ago may now be navigating the same essentials on roughly a third of that. The middle class here is less a stable economic stratum than a holding pattern, people who have moved out of poverty but have not moved into financial resilience.

The companies that built for the assumed middle class found this out painfully. Jumia, once described as the Amazon of Africa, has struggled significantly with unit economics and customer retention. Copia and Sendy have both shut down operations in key markets. These were not bad companies. They were companies built around a consumer class that was considerably thinner and more precarious than the addressable market slide suggested.

Why Africa's Femtech Market Is Misread by Investors and Founders

The femtech sector, broadly defined as technology built to address women's health, is growing fast globally. The global market is valued at around $60 billion in 2025 and forecast to reach $140 billion by 2035. The pitch for Africa is compelling: 583 million women on the continent, rising smartphone penetration, high rates of maternal mortality and reproductive health challenges, and healthcare systems that are visibly inadequate. Investment should be flowing.

And yet Africa accounts for just 2% of the global femtech market, and only $10 million tracked went to femtech companies on the continent in 2023, according to UNICEF.

That funding gap is partly about investor bias and perception of risk. But there is something else happening too. Many of the femtech companies that have launched in Africa have brought the same billion-consumer assumption with them. They have built subscription apps, premium wellness platforms, and direct-to-consumer models that require exactly the kind of stable, digitally active, disposable-income-holding consumer that is far rarer than the slides suggest.

"In Africa, D2C apps succeed only when there is higher disposable income, wider insurance coverage, and strong e-commerce penetration. Selling directly to women without solving for affordability, distribution, trust channels — that isn't going to scale."Margaret Ntambi, via Techpoint Africa

The Real Healthcare Access Crisis Facing African Women

The baseline context makes this even harder. A 2026 pooled analysis across multiple Sub-Saharan African countries found that over 55% of women face meaningful barriers to accessing healthcare. This is not a digital health problem. It is a structural economic one.

WHO data shows that out-of-pocket payments account for over a quarter of health spending in 31 African countries, and in 11 of those, it exceeds half of all health spending.

The same report found that between 2000 and 2019, the number of people pushed into poverty by healthcare costs rose every year. About half of all people globally impoverished by healthcare costs live in Africa.

For women specifically, the numbers are stark. A single maternal healthcare visit in Sub-Saharan Africa can cost roughly a full month of earnings for a low-income woman. In East Africa, financial barriers to care disproportionately affect women of reproductive age, the exact demographic that femtech companies are trying to serve. A 2025 study found that 30% of rural women delay seeking care due to distance and fees combined.

These are not edge cases or niche demographics. They describe the majority experience. When a femtech founder builds a $9-per-month period tracking app, or a $15 telehealth consultation model, and aims it at the "580 million women in Africa," they are aiming at a population that, for the most part, is weighing healthcare costs against food and transport, not opting for premium digital wellness.

How the Billion Consumer Myth Distorts Femtech Funding in Africa

There is a particularly frustrating paradox at the heart of this. The billion-consumer narrative inflates optimism about the addressable market, which should attract more investment. Instead, it ends up producing the wrong kind of investment, and in some cases, no investment at all.

When investors hear "Africa femtech has a 580 million woman addressable market," many of them implicitly layer on Western assumptions about what those women can spend, how they access products, and what business models will work. They fund consumer app plays, D2C models, and subscription platforms. Those models fail when they hit the actual economic conditions on the ground. The investors conclude that "Africa femtech doesn't work." They pull back.

The real need, for affordable, high-volume, embedded, essentials-first healthcare solutions, goes underfunded.

UNICEF reports that 75% of femtech companies are currently based in the US or Europe, and globally, only 3% of digital health funding goes to femtech at all. For Africa, it is even thinner. Even in the US, just 2% of venture capital funding goes to women-led startups.

Add geography into that, and you begin to understand why only 9 of the 28 confirmed active African femtech startups have received any funding, per Veriva Africa's 2024 landscape report.

What African Femtech Startups Get Wrong Because of This Myth

Beyond funding, the myth shapes what actually gets built. A recent analysis of the African femtech landscape found that around 81% of funded startups are focused on fertility, the category with the most "premium" story and the most direct Western comparator.

Meanwhile, menopause, pelvic health, endometriosis, and postpartum mental health are almost invisible to investors, despite affecting millions of women on the continent today.

Postpartum depression affects up to 25% of women in some African settings, per the same analysis. After leaving hospital, most women receive no structured follow-up and no mental health screening. The market for postpartum support exists. The financing and product development attention largely does not.

A broader critique of femtech globally is that most apps are built with English-speaking, cisgender, middle-class users in mind, and very few are designed for women in low-income or rural regions despite those being the communities with the greatest health access gaps. Africa is not an exception to this pattern. In many ways, the continent is its most expensive expression.

There is also a research problem layered on top. Much of the clinical research shaping women's health innovation globally was conducted outside African populations, meaning that even well-funded products enter African markets built on assumptions about biology and health behaviour that may not hold.

What Actually Works in African Women's Health and Femtech

The companies that have found meaningful traction in African women's health share a few things in common. They did not build for the imagined consumer. They built for the one that actually exists.

M-Pesa is the most cited example in any conversation about African market realities, and for good reason. It solved a basic, widespread, immediately valuable problem at a price point people could manage. The lesson for femtech is not "build a payments product." It is: build for essentials, design for the actual price tolerance of your actual user, and do not require infrastructure that does not yet exist.

Kasha, operating in Rwanda and Kenya, distributes contraceptives and menstrual health products directly to women's homes, with an optional offline text service for women without smartphones. That offline fallback is not a limitation. It is the product. It reflects an accurate understanding of who the user actually is.

The B2B and institutional model is consistently cited by practitioners as the most viable route to scale in African femtech, embedding products into employers, insurers, NGOs, and governments rather than expecting individual women to pay subscription fees from limited personal income. This is not a compromise. It is an accurate response to who holds healthcare-related purchasing power in these economies.

Population size, as the consumer businesses that collapsed have learned, is a vanity metric without purchasing power context. A startup targeting 50,000 women who can actually afford and sustain using a product is a better business than one targeting 10 million women who cannot. The sober, granular thinking applies in healthcare more than anywhere else, because the stakes are not just commercial.

A femtech company that overpromises, under-delivers, and shuts down does not just disappoint investors. It leaves a gap in women's healthcare access that was already inadequate to begin with.

The African Femtech Opportunity Is Real. The Framing Is Broken.

None of this is an argument against investing in African femtech. The opposite is true. The need is enormous, the current provision is inadequate, and the gap between what exists and what is required is arguably the largest genuine market opportunity on the continent.

Research has shown women are 75% more likely than men to use digital tools for health-related information. The demand is real. The willingness is real. The infrastructure gap and economic precarity are also real.

The problem is the narrative. "580 million women" is a number that sounds like a market. It is actually a population. Converting a population into a sustainable market requires understanding what those women earn, how they spend, what they already pay for healthcare, what they trust, and what problem is urgent enough that they will prioritise it.

Most African femtech startups have not done that work rigorously enough, because the billion-consumer myth made it seem unnecessary.

Founders and investors who approach the continent with sober, data-driven, granular thinking will find something the optimistic deck-builders keep missing. The opportunity is not smaller than advertised. In many ways it is larger. But it requires building for the woman who actually exists, rather than the consumer the headline assumes.

---

Hi, I'm Gigi. If you made it this far, I'm happy you did. I'm a marketing lead and founder of Asele (a women's health platform for African women and beyond) and my journey into building out the product and everything else has taught me some things and I'm trying my best to share my experiences. You can learn more about Asele and download our period tracker on Google Play Store, we also have a web app available that works on any device. :)